Measured endpoints are tied to a particular task, population, and exposure. A finding cannot be generalized to a different outcome without supporting evidence.
The studied higher-dose arm improved the primary short-term outcome compared with the low-dose control, with adverse events and unresolved durability. Source
Evidence type
Human research
Population
Adults with treatment-resistant depression in the phase 2 trial
Exposure
Single 25 mg psilocybin administration with psychological support versus 1 mg control; week 3
The higher-dose study arm reduced depression severity relative to the low-dose control at the primary time point. Treatment-resistant depression; standardized preparation and psychological support; assessment at week 3.